Company Info

Leadership Team

Douglas A. Hamilton, B.Sc., MBA

President and Chief Executive Officer

Mr. Hamilton was appointed President and Chief Executive Officer of the company on June 17, 2015 and has consulted for the company as acting Chief Financial Officer since August 2014. Mr. Hamilton has over 20 years experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as CFO for SEA Medical Systems, a Silicon Valley health-tech company. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox® and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend® and Zithromax® product teams at Pfizer, in addition to the Aranesp®, Epogen®, Stemgen®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.

Michael J. Donovan, Ph.D., M.D.

Acting Chief Medical Officer

Dr. Donovan joined the company as acting chief medical officer in August 2015. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid-based assays and coupled mathematic applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.

In addition to an academic career at Harvard Medical School and Boston Children's Hospital, Dr. Donovan has over 20 years' experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of Exosome Diagnostics, Inc. and Chief Scientific Officer for Aureon Biosciences Corporation.

Dr. Donovan graduated from Rutgers University with a BS in zoology, a MS in endocrinology and a PhD in cell and developmental biology. He received his M.D. from the University of Medicine and Dentistry of New Jersey.

Daniel H. Schneiderman

Vice President of Finance & Corporate Secretary

Mr. Schneiderman was appointed Vice President, Finance effective December 21, 2012 and has served as the Company's Vice President, Comptroller and Secretary since February 27, 2012. Mr. Schneiderman has fifteen years of investment banking and corporate finance experience, focusing on private and public equity for small and mid-market capitalization companies mainly in the healthcare and life sciences sectors. Prior to joining the Company, he was senior vice president of investment banking for Burnham Hill Partners LLC, where he worked since 2008. From 2004 through 2008, Mr. Schneiderman was vice president of investment banking at Burnham Hill Partners, a division of Pali Capital, Inc. At Burnham Hill Partners, Mr. Schneiderman worked on over 100 transactions raising over $500 million for public and private companies through direct principal investments, PIPEs, registered directs, Reg D offerings, and restructurings. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an analyst and began his finance career at a distressed debt and event-driven hedge fund in San Francisco. Mr. Schneiderman holds a Bachelor's Degree in Economics from Tulane University. Mr. Schneiderman serves as a board member of Unleashed NY, a non-profit located in New York.

Rick Pierce

Vice President of Investor Relations

Mr. Pierce joined the company as vice president of investor relations as of March 1, 2015. Mr. Pierce is the founder of FEP Capital Advisors, LLC, which provides investor relations and corporate development services to biotech, specialty pharmaceuticals and medical device companies. He has been involved in the up-listing of two OTCBB listed companies to the NASDAQ and NYSE stock exchanges. Mr. Pierce has 29 years of experience in specialty pharma, biotech, medical device and diagnostics operations and finance. He has a comprehensive understanding and broad exposure to most aspects of medical device and drug development from preclinical development, chemistry and manufacturing controls, through commercial product launch. Prior to entering industry in 1998, Mr. Pierce spent several years on Wall Street at firms including Merrill Lynch and Lehman Brothers, where he placed over a billion dollars in equity and debt securities. He has extensive capital markets and investment banking experience including, IPOs, secondary offerings, PIPEs, M&A, sales and trading. He has been involved in U.S./cross border pharmaceutical and biotech business development since 1994 and involved in closing a number of strategic transactions. At his last three companies Javelin Pharmaceuticals, Inc., SemBioSys Genetics and GlycoGenesys, Inc., Mr. Pierce helped raise more than $335 million dollars and successfully close a number of transformative business development deals, including the buyout of Javelin Pharmaceuticals by Hospira (now Pfizer).